Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
NewAmsterdam Pharma Company N.V. - Ordinary Shares
(NQ:
NAMS
)
16.26
-0.27 (-1.63%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about NewAmsterdam Pharma Company N.V. - Ordinary Shares
< Previous
1
2
Next >
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
August 07, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
July 29, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
July 26, 2024
Company to host conference call on Monday, July 29 at 8:30 a.m. ET
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
July 18, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors
July 08, 2024
-- Company expects to report topline data in the first quarter of 2025 --
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 03, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office
June 11, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
May 29, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
May 21, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
May 09, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
May 02, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
April 09, 2024
Enrollment to continue to the end of April to accommodate strong patient and site interest
From
NewAmsterdam Pharma N.V
Via
GlobeNewswire
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
April 01, 2024
From
NewAmsterdam Pharma N.V
Via
GlobeNewswire
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
March 25, 2024
From
NewAmsterdam Pharma N.V
Via
GlobeNewswire
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
March 12, 2024
From
NewAmsterdam Pharma N.V
Via
GlobeNewswire
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
February 28, 2024
From
NewAmsterdam Pharma N.V
Via
GlobeNewswire
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March
February 26, 2024
From
NewAmsterdam Pharma N.V
Via
GlobeNewswire
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
February 13, 2024
From
NewAmsterdam Pharma N.V
Via
GlobeNewswire
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
February 13, 2024
From
NewAmsterdam Pharma N.V
Via
GlobeNewswire
NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 01, 2024
From
NewAmsterdam Pharma N.V
Via
GlobeNewswire
NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors
January 08, 2024
From
NewAmsterdam Pharma N.V
Via
GlobeNewswire
NewAmsterdam Pharma Announces 2024 Strategic Priorities
January 04, 2024
From
NewAmsterdam Pharma N.V
Via
GlobeNewswire
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights
November 13, 2023
From
NewAmsterdam Pharma N.V
Via
GlobeNewswire
NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer
October 23, 2023
From
NewAmsterdam Pharma N.V
Via
GlobeNewswire
NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation
September 21, 2023
From
NewAmsterdam Pharma N.V
Via
GlobeNewswire
NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference
September 20, 2023
From
NewAmsterdam Pharma N.V
Via
GlobeNewswire
NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer
August 14, 2023
From
NewAmsterdam Pharma Company B.V.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.